Based on this, fluvastatin-induced impairment of CPT2-dependent FAO in the skeletal muscles may lead to elevated FFAs and acylcarnitines, which, in addition to ROS, contribute to activated Pkcdelta-mediated inhibition of skeletal muscle chloride channels and subsequent myopathy-like phenotypes. The gene discussed is CPT2; the disease is myopathy.